George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 218.00
Bid: 215.00
Ask: 217.50
Change: 5.50 (2.59%)
Spread: 2.50 (1.163%)
Open: 219.50
High: 219.50
Low: 207.00
Prev. Close: 212.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

Fri, 17th Nov 2023 07:58

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

UK retail sales declined last month despite expectations of a month-on-month increase, and declined faster than expected on an annual basis, official numbers on Friday showed.

"Cost of living pressures, reduced footfall and the great British weather all played their part. There are signs that cracks are starting to appear in the economy with consumers tightening their belts and switching to cheaper brands. Consumers are still spending more and getting less with retail sales volumes now at their lowest level since February 2021," said Wealth Club's Charlie Huggins.

Meanwhile, Swissquote Bank analyst Ipek Ozkardeskaya was upbeat ahead of the final day of trading this week, particularly when reflecting upon the week's news coming out of the US.

"This week could hardly be better in terms of economic, political, and geopolitical news. The US inflation slowed more than expected, the US politicians inked a short-term deal to avert a shutdown," said Ozkardeskaya.

"On top, the US retail sales fell last month, but fell less than expected, the initial jobless claims rose, and the US unemployment benefits reached the highest level in almost two years, factory production fell more than expected and homebuilder sentiment fell to the lowest level for the year."

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called up 0.4% at 7,441.17

----------

Hang Seng: down 2.1% at 17,452.71

Nikkei 225: closed up 0.5% at 33,585.20

S&P/ASX 200: closed down 0.1% at 7,049.40

----------

DJIA: closed down 45.74 points, or 0.1%, at 34,945.47

S&P 500: closed up 5.36 points, or 0.1%, at 4,508.24

Nasdaq Composite: closed up 9.84 points, or 0.1%, at 14,113.67

----------

EUR: down at USD1.0839 (USD1.0840)

GBP: down at USD1.2377 (USD1.2398)

USD: down at JPY150.50 (JPY151.34)

Gold: up at USD1,986.42 per ounce (USD1,966.26)

(Brent): down at USD77.41 a barrel (USD80.84)

(changes since previous London equities close)

----------

ECONOMICS

----------

Friday's key economic events still to come:

10:00 CET EU balance of payments

11:00 CET EU CPI

08:30 EST US housing starts

08:30 CST US Fed Chicago President Austan Goolsbee speaks

10:00 EST US advance quarterly services

US FRB Boston President Susan Collins speaks

US Federal Reserve Board Vice Chair Michael Barr speaks

UK BoE Deputy Governor David Ramsden speaks

----------

According to the Office for National Statistics, retail sales volumes declined 2.7% year-on-year in October, quickening from a 1.3% decline in September. The September figure was revised from a previous 1.0% decline. The October read also came in worse than feared, with market expectations of a 1.5% decline, according to FXStreet-cited consensus. Retail sales declined 0.3% in October from September, falling short of consensus. A monthly increase of 0.3% was forecast, according to FXStreet. In September, retail sales had fallen 1.1% from August, revised from a previous 0.9% decline. "Non-food stores sales volumes fell by 0.2% in October 2023, following a 2.1% fall in September 2023; retailers suggested that cost of living, reduced footfall and the wet weather in the second half of the month contributed to the fall," the ONS noted.

----------

US President Joe Biden has signed a temporary spending bill a day before a potential government shutdown. The move pushes a fight with congressional Republicans over the federal budget into the new year, and wartime aid for Ukraine and Israel remains stalled. The measure passed the US house and senate by wide bipartisan margins this week, ensuring the government remains open until after the holiday season. It also potentially giving legislators more time to sort out their considerable differences over government spending levels for the current fiscal year. Biden signed the bill in San Francisco, where he is hosting the summit of Asia-Pacific Economic Co-operation economies.

----------

BROKER RATING CHANGES

----------

Barclays raises NatWest to 'overweight' (equal weight) - price target 330 (315) pence

----------

Barclays raises Babcock International to 'overweight' (equal weight) - price target 529 (325) pence

----------

Jefferies cuts Great Portland Estates to 'underperform' (hold) - price target 352 (387) pence

----------

COMPANIES - FTSE 100

----------

AstraZeneca said its Truqap treatment for patients with advanced hormone receptor positive breast cancer, in combination with Faslodex, has been approved by the US Food & Drug Administration. This follows the results from its CapItello-291 phase 3 trial published earlier this year, which showed reduced risk of disease progression or death by 50% compared to Faslodex alone. AstraZeneca Executive Vice President, Oncology Business Unit Dave Fredrickson commented: "The rapid US approval of Truqap reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test patients at the time of diagnosis, as up to fifty per cent have tumours with these alterations. As a first-in-class medicine, this approval provides a critical new option for patients in the US with this specific type of disease and we look forward to bringing Truqap to the many breast cancer patients who can benefit across the globe."

----------

COMPANIES - FTSE 250

----------

PureTech Health said its founded entity Karuna Therapeutics has announced positive results from its phase 1b ambulatory blood pressure monitoring trial of KarXT in treating schizophrenia. The biotechnology firm said results demonstrate that KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia. This is alongside meeting its primary endpoint of demonstrating a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of negative 0.59 millimetres of mercury. It said KarXT was "generally well tolerated", with a side effect profile consistent with prior trials in the Emergent programme evaluating KarXT in schizophrenia.

----------

OTHER COMPANIES

----------

FRP Advisory said its performance was strong during the half-year that ended October 31. The corporate finance, restructuring and debt adviser said it expects first half revenue of GBP58.7 million, up 19% from GBP49.4 million a year earlier, alongside underlying adjusted earnings before interest, tax, depreciation and amortisation rising 34% to GBP15.5 million from GBP11.6 million. It noted the restructuring having seen an increase in activity levels during calendar 2023, including administrations approaching pre-pandemic levels. The company said: "Companies with significant borrowings who have rolled off lower interest rate arrangements are now subject to much higher debt service costs, with interest rates now considerably higher than the 2009-2021 period...Certain sectors such as construction, property, casual dining and food service, retail, administrative and support services are finding current trading conditions particularly challenging." Chief Executive Officer Geoff Rowley added: "We remain confident of making further progress, with leading positions in our core markets and a team and structure that leaves us well positioned to support corporates through the business cycle and respond to increased demand for our services."

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Apr 2024 10:07

Puretech Health operating losses narrow in 'landmark year'

(Sharecast News) - Biotechnology company Puretech Health said on Thursday that 2023 had been "a landmark year" for the group, making "strong strategic and clinical progress".

Read more
25 Apr 2024 09:59

PureTech touts "momentum" as grants shrivel but annual loss narrows

(Alliance News) - PureTech Health PLC on Thursday maintained an optimistic outlook for the year ahead, despite seeing annual revenue fall.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
18 Apr 2024 14:17

UK earnings, trading statements calendar - next 7 days

Friday 19 April 
888 Holdings PLCTrading Statement
Man Group PLCTrading Statement
Monday 22 April 
Brave Bison Group PLCFull Year Results
Elixirr International PLCFull Year Results
Frenkel Topping Group PLCFull Year Results
Mobico Group PLCFull Year Results
South32 LtdQ3 Results
Ten Lifestyle Group PLCHalf Year Results
Tuesday 23 April 
Alliance Pharma PLCFull Year Results
Alphawave IP Group PLCFull Year Results
Anglo American PLCTrading Statement
ASA International Group PLCFull Year Results
Associated British Foods PLCHalf Year Results
Eleco PLCFull Year Results
GB Group PLCTrading Statement
Jupiter Fund Management PLCTrading Statement
Maintel Holdings PLCFull Year Results
Property Franchise Group PLCFull Year Results
Taylor Wimpey PLCTrading Statement
tinyBuild IncFull Year Results
Trellus Health PLCFull Year Results
Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Hikma Pharmaceuticals PLCTrading Statement
Focusrite PLCHalf Year Results
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
16 Apr 2024 21:57

EARNINGS AND TRADING: J Smart boosts revenue, Tertiary starts drilling

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
11 Apr 2024 13:01

US FDA hands fast track to PureTech head and neck cancer treatment

(Alliance News) - PureTech Health PLC on Thursday said that its LYT-200 cancer treatment has received a significant endorsement from the US drugs regulator.

Read more
9 Apr 2024 11:33

PureTech Health CEO Zohar moves to head-up portfolio firm Seaport

(Alliance News) - PureTech Health PLC on Tuesday said its founding chief executive officer, Daphne Zohar, will shift to become CEO of Seaport Therapeutics, a biopharmaceutical company founded by PureTech.

Read more
9 Apr 2024 07:48

PureTech founder steps down as CEO to lead SeaPort spin-off

(Sharecast News) - Clinical-stage biotherapeutics group PureTech has announced that its founding chief executive is to step down to lead SeaPort Therapeutics, a PureTech company she founded that has just raised $100m in Series A financing.

Read more
19 Mar 2024 16:57

LONDON MARKET CLOSE: European large-caps rise on eve of Fed decision

(Alliance News) - Blue-chip stock prices in Europe closed higher on Tuesday, showing little signs of nerves ahead of Wednesday's Federal Reserve decision and UK inflation reading.

Read more
19 Mar 2024 11:16

PureTech shares jump on USD100 million tender offer proposal

(Alliance News) - PureTech Health PLC on Tuesday said it plans to return USD100 million to shareholders with a tender offer, starting after it publishes its annual report in April.

Read more
19 Mar 2024 09:46

Puretech Health proposes $100m capital return

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

Read more
13 Mar 2024 12:27

PureTech Health celebrates drug designation for LYT-200 from US FDA

(Alliance News) - PureTech Health PLC on Wednesday touted the efficacy of its acute myeloid leukaemia therapy, after securing a regulatory designation from the US Food & Drug Administration.

Read more
27 Feb 2024 11:28

PureTech notes positive results from Shionogi's EndeavorRx ADHD trial

(Alliance News) - PureTech Health PLC on Tuesday noted that its founded entity, Akili Inc, has announced positive results from a phase 3 clinical trial of EndeavorRx for children with attention deficit hyperactivity disorder in Japan.

Read more
20 Dec 2023 09:53

PureTech makes strong progress, expects "multiple catalysts" next year

(Alliance News) - PureTech Health PLC on Wednesday said it made "strong strategic and clinical progress" in 2023, and predicted "a productive and exciting" tear to come.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.